<DOC>
	<DOCNO>NCT02907021</DOCNO>
	<brief_summary>Trastuzumab important treatment HER 2 positive breast cancer . But trastuzumab cause injury heart , one main reason administer plan . Heart injury often successfully treat use cardiac medication . The aim SCHOLAR evaluate whether safe continue trastuzumab individual mild moderate cardiac injury , treat appropriate cardiac medication . In way investigator hope able optimise delivery treatment patient breast cancer prove survival benefit , especially administer full 12-month course .</brief_summary>
	<brief_title>Safety Continuing CHemotherapy Overt Left Ventricular Dysfunction Using Antibodies HER-2</brief_title>
	<detailed_description>The SCHOLAR study design modify phase I , non-randomized clinical study . Initially cohort 5 participant enrol . They continue receive trastuzumab . All participant SCHOLAR also prescribe standard-of-care treatment patient LV systolic dysfunction , include beta-blocker , carvedilol , ACE-I , ramipril , tolerate , maximum dos tolerate , carvedilol 25mg BID ramipril 10mg daily . If time 1 first 5 participant develop cDLT , de-escalation occur . De-escalation involve change eligibility criterion exclude patient LVEF &lt; 45 % patient NYHA class II , III , IV heart failure . A 5 patient recruit . If 2 second 5 participant develop cDLT de-escalation , intervention consider unsafe , study close . If intervention consider safe either use initial eligibility criterion de-escalated eligibility criterion , study close 20 participant recruit . If time study &gt; 20 % participant develop cDLT , intervention consider unsafe , study close . Patients see cardiologist follow time point ( referenced baseline visit ) : baseline , 3 week ± 1 week , 6 week ± 1 week , 3 month ± 1 week , 6 month ± 1 week , 9 month ± 1 week , 12 month ± 1 week</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Stage IIII HER2 positive breast cancer Receiving adjuvant therapy trastuzumab Provide inform consent Exhibit LV dysfunction evidence either LVEF 40 % low limit normal ( i.e . &lt; 54 % woman &lt; 52 % men18 ) , LVEF within normal limit ( i.e . ≥54 % woman ≥52 % men ) NYHA class II heart failure symptom within past year , A fall LVEF ≥15 % baseline Patients eligible SCHOLAR following : NYHA class III IV heart failure Systolic blood pressure &lt; 90mmHg Current use ACEI/angiotensin receptor blocker betablocker Contraindication ACEI/angiotensin receptor blocker betablocker</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>